ArticleCancer medicine2022

Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.

Yurong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.